Friday, 19 Jul 2019

You are here

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect. It is known that this loss of response is associated with reduced serum pegloticase levels (https://arthritis-research.biomedcentral.com/articles/10.1186/ar4497).

The investigators of the TRIPLE trial pose the question of whether an additional dose of 8 mg of pegloticase given in between the first and second doses would help to maintain serum pegloticase levels and therefore persistent urate lowering effect.

Dr. Kenneth Saag presented data from the TRIPLE study this morning. This is a multi-center, open label trial enrolling patients with chronic gout unable to maintain a serum uric acid level of 6 mg/dL or less. After discontinuing their background urate lowering agents, subjects received 3 weekly infusions of pegloticase 8 mg followed by biweekly doses to total 10 doses over 17 weeks. sUA was measured just before each dose and subsequent doses were given only if levels remained ≤6mg/dL. Serum pegloticase levels were also measured before each dose.

 

Results for the first 50 subjects were presented and included 22 responders, 21 non-responders and 7 subjects who dropped out. They found that subjects who responded had higher trough levels of pegloticase, and that levels 1-week post-infusion predicted responsiveness to the drug, with an overall response rate of 44% in subjects who received the additional dose. I think we will all be anxiously awaiting more results of this study!

Add new comment

More Like This

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.